Theriva Biologics (TOVX) Accounts Payables (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Accounts Payables of $608000.0 for Q1 2026, up 39.13% year-over-year from $437000.0 in Q1 2025, and down 40.04% quarter-over-quarter from $1.0 million in Q4 2025.
Theriva Biologics (TOVX) Accounts Payables (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Accounts Payables for 17 consecutive years, with $608000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 39.13% year-over-year to $608000.0; the TTM figure through Mar 2026 stood at $608000.0 (up 39.13% YoY), while the FY2025 annual figure was $1.0 million, up 18.04% from the prior year.
- Accounts Payables slipped to $608000.0 in Q1 2026 per TOVX's latest filing, from $1.0 million in the prior quarter.
- Across five years, Accounts Payables topped out at $1.4 million in Q1 2022 and bottomed at $437000.0 in Q1 2025.
- Historically, Accounts Payables has averaged $791058.8 across 5 years, with a median of $770000.0 in 2022.
- Annual changes were most pronounced in 2022 — Accounts Payables surged 118.04% — and 2023, when it tumbled 64.55%.
- Theriva Biologics' Accounts Payables stood at $915000.0 in 2022, then dropped by 15.85% to $770000.0 in 2023, then advanced by 11.56% to $859000.0 in 2024, then rose by 18.04% to $1.0 million in 2025, then tumbled by 40.04% to $608000.0 in 2026.
- Business Quant data shows TOVX's Accounts Payables at $608000.0 in Q1 2026, $1.0 million in Q4 2025, and $795000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | 984,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 984,000.00 |
| Mar 31, 2026 | 608,000.00 |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 795,000.00 |
| Jun 30, 2025 | 607,000.00 |
| Mar 31, 2025 | 437,000.00 |
| Dec 31, 2024 | 859,000.00 |
| Sep 30, 2024 | 756,000.00 |
| Jun 30, 2024 | 935,000.00 |
| Mar 31, 2024 | 571,000.00 |
| Dec 31, 2023 | 770,000.00 |
| Sep 30, 2023 | 833,000.00 |
| Jun 30, 2023 | 741,000.00 |
| Mar 31, 2023 | 480,000.00 |
| Dec 31, 2022 | 915,000.00 |
| Sep 30, 2022 | 770,000.00 |
| Jun 30, 2022 | 1.00 Mn |
| Mar 31, 2022 | 1.35 Mn |
| Dec 31, 2021 | 524,000.00 |
| Sep 30, 2021 | 1.26 Mn |